Wyse, PhD, J. J., B. J. Morasco, PhD, S. K. Dobscha, MD, M. I. Demidenko, BS, T. H. A. Meath, MPH, and T. I. Lovejoy, PhD, MPH. “Provider Reasons for Discontinuing Long-Term Opioid Therapy Following Aberrant Urine Drug Tests Differ Based on the Type of Substance Identified”. Journal of Opioid Management, vol. 14, no. 4, July 2018, pp. 295-03, doi:10.5055/jom.2018.0461.